Related Experiment Video

Updated: May 13, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas

Arti Shukla1, Jill M Miller, Christopher Cason

  • 1Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont 05405, USA. Arti.Shukla@med.uvm.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 1, 2013
PubMed
Abstract

Insights

Extracellular signal-regulated kinase 5 (ERK5) is crucial for malignant mesothelioma growth. Inhibiting ERK5 enhances chemotherapy effectiveness and reduces tumor progression, offering a promising new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Malignant mesothelioma is an aggressive cancer with limited treatment options.
  • New therapeutic targets are urgently needed to improve patient outcomes.
  • Extracellular signal-regulated kinase 5 (ERK5) plays a role in cellular processes relevant to cancer.

Purpose of the Study:

  • To investigate the role of ERK5 in malignant mesothelioma tumor growth.
  • To evaluate ERK5 as a potential therapeutic target for malignant mesothelioma.
  • To assess the efficacy of combining ERK5 inhibition with chemotherapy.

Main Methods:

  • Utilized mesothelial and mesothelioma cell lines.
  • Employed xenograft severe combined immunodeficient (SCID) mouse models.
  • Investigated ERK5 activation by asbestos and doxorubicin.
  • Assessed the effects of ERK5 silencing (shERK5) on cell behavior and gene expression.
  • Evaluated combination therapy with ERK5 inhibition and chemotherapeutic drugs.

Main Results:

  • Malignant mesothelioma cells exhibit constitutive ERK5 activation, further enhanced by doxorubicin.
  • ERK5 silencing increased doxorubicin-induced cell death and drug retention.
  • shERK5 cells showed reduced colony formation, invasion, and modulated gene expression.
  • Tumor growth was significantly reduced in mice bearing shERK5 mesothelioma cells.
  • ERK5 inhibition, combined with doxorubicin and cisplatin, further reduced tumor burden.

Conclusions:

  • ERK5 is a critical regulator of malignant mesothelioma progression and drug resistance.
  • Inhibiting ERK5 is a viable strategy to enhance chemotherapy efficacy.
  • Combination therapy involving ERK5 inhibition holds promise for treating malignant mesothelioma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...